Patupilone (Epothilone B)

Catalog No.S1364 Synonyms: EPO906

For research use only.

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

Patupilone (Epothilone B) Chemical Structure

CAS No. 152044-54-7

Selleck's Patupilone (Epothilone B) has been cited by 13 publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Other Microtubule Associated Products

Biological Activity

Description Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.
Targets
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
In vitro

Epothilone B shows better activity than Epothilone A. The EC0.01 of Epothilone B is 1.8 μM. Epothilone B potently inhibits cell proliferation in HCT116 cells, with IC50 of 0.8 nM. [1] Epothilone B induces mitotic arrest and displays cytotoxicity in KB3-1, KBV-1, Hela, and Hs578T cells, with IC50 of 3 nM to 92 nM. Epothilone B competes with Taxol in binding to microtubules, with IC50 of 3.3 μM. [2] In MCF-7 cells overexpressing GFP-α-tubulin, Epothilone B (3.5 nM) efficiently blocks microtubule dynamics. Meanwhile, Epothilone B induces mitotic arrest with IC50 of 3.5 nM. [3] In multiple myeloma (MM) cells, including RPMI 8226, U266, MM.1S, LR5, and MR20, Epothilone B directly suppresses proliferation with IC50 of 1 nM to 10 nM. Similarly, Epothilone B (10 nM) also induces cell cycle arrest and apoptosis. [4] A recent study reveals that, in ovarian cancer Hey cells, Epothilone B (5 nM–100 nM) enhances surface epithelial cell adhesion antigen (EpCAM), without affecting the transcription or the total cellular level of EpCAM. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell M3jQdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEWw[4NKdmirYnn0bY9vKG:oIHj1cYFvKEyFLUKtZYQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd5ZT2wOkDPxE1? MmfOV2FPT0WU
human A431 cell MmLGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYfJcohq[mm2aX;uJI9nKGi3bXHuJGE1OzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Lki2[U0xPiEQvF2= M{H4UnNCVkeHUh?=
human SW1710 cell NWrKb2p[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYHJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVRmNTB3IN88US=> M1H6N3NCVkeHUh?=
human Daoy cell NX\6OVlRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXvJcohq[mm2aX;uJI9nKGi3bXHuJGRid3liY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3Ojef-8kEBKSzVyPUKuO|NmNTB3IN88US=> NYTkZolPW0GQR1XS
human BFTC-905 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYrE[mtXUW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwOUnlMVA2KM7:TR?= MV3TRW5ITVJ?
human A375 cell M1\rcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHrreWhKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21[U0xPSEQvF2= MWXTRW5ITVJ?
human RKO cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoHGTY5pcWKrdHnvckBw\iCqdX3hckBTU09iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkS3[U0xPSEQvF2= NEfpcHNUSU6JRWK=
human KYSE-510 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3fDOWlvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT21NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjN6ZT2wOUDPxE1? Ml3YV2FPT0WU
human HLE cell NFjmS25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRThwMk\lMVA2KM7:TR?= NUHieoRGW0GQR1XS
human MCF7 cell NGLoPGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFzDXppKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlY3\S1yNTFOwG0> MoLRV2FPT0WU
human 786-0 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVn4c3F3UW6qaXLpeIlwdiCxZjDoeY1idiB5OE[tNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTFibl2= M2PTWXNCVkeHUh?=
human TE-8 cell MnjFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4jQO2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVEyKG6P MUDTRW5ITVJ?
ovarian carcinoma 1A9 cell MoPuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4nC[GlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IH;2ZZJq[W5iY3HyZ4lvd22jIEHBPUBk\WyuIHfyc5d1cA>? NIXOXHkyPjF|NEmyPC=>
human PANC-03-27 cell MlzZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NETiTphKdmirYnn0bY9vKG:oIHj1cYFvKFCDTlOtNFMuOjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGzNkDPxE1? NWmzd|Z3W0GQR1XS
human VMRC-RCZ cell NWXkZ4dkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHe4NGpKdmirYnn0bY9vKG:oIHj1cYFvKF[PUlOtVmNbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zM{[g{txO MUHTRW5ITVJ?
human IGROV-1 cell NYrQOG9WT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVu3VIx[UW6qaXLpeIlwdiCxZjDoeY1idiCLR2LPWk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNU[g{txO NYTpZVVoW0GQR1XS
human MG-63 cell NHT3bZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWPJSJJ7UW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTZ3IN88US=> NGf2doFUSU6JRWK=
human SIG-M5 cell NHPPTpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4PBb2lvcGmkaYTpc44hd2ZiaIXtZY4hW0mJLV21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPjlizszN MYrTRW5ITVJ?
human NCI-H650 cell NWmxPZh6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmfGTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTdizszN NXS1cJRJW0GQR1XS
human PSN1 cell NHG2dFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MojjTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xO|Mh|ryP MYDTRW5ITVJ?
human PA-1 cell NFvMc|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFK2c2FKdmirYnn0bY9vKG:oIHj1cYFvKFCDLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE4PCEQvF2= NGXmbIdUSU6JRWK=
KB-8511 cells MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV\M[nRDPzJiaB?= NXTmPHc3S2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JJRp\SCpcn;3eIghd2ZicHHjcIl1[XinbD3y[ZNqe3SjboSgbJVu[W5iZYDp[IVzdW:rZDDjZZJkcW6xbXGgZ4VtdHNiS1KtPFUyOSCkeTC1NEBx\XKlZX70JEg4OiCqcjDlfJBwe3W{ZTmsJGlEPTB;MD6xPEDPxE1? M{\rPFEyOTN|MEi2
KB-31 cells NVvzc3JUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4HCUVczKGh? M3KyXmNwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDD0bIUh\3Kxd4ToJI9nKHCjY3zpeIF5\Wxvc3Xud4l1cX[nIHj1cYFvKGWyaXTldo1wcWRiY3HyZ4lvd22jIHPlcIx{KEuELUOxJIJ6KDVyIIDldoNmdnRiKEeyJIhzKGW6cH;zeZJmMQ>? NEfPWWEyOTF|M{C4Oi=>
human BHY cell MlLRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmXHTY5pcWKrdHnvckBw\iCqdX3hckBDUFliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG5OUBvVQ>? NUTFS3Y6W0GQR1XS
human BB30-HNC cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2rSS2lvcGmkaYTpc44hd2ZiaIXtZY4hSkJ|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJyMTFOwG0> NEDKc4lUSU6JRWK=
human HOS cell M3\NV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlGxTY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKxOUDPxE1? MmjhV2FPT0WU
human 639-V cell NW\M[pdIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2fxbmlvcGmkaYTpc44hd2ZiaIXtZY4hPjN7LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIyQCEQvF2= MXfTRW5ITVJ?
human ES1 cell  NXztW5BNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGnnZlBKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlIyKM7:TR?= NFjGOVZUSU6JRWK=
human TE-15 cell  MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWPJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTF3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlUh|ryP NVL4eWZ{W0GQR1XS
human LXF-289 cell M3XVTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmDSTY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPzdizszN M3PofnNCVkeHUh?=
human CAL-12T cell NYDzS4E6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3\0VGlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUGyWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN7IN88US=> MX3TRW5ITVJ?
human T84 cell MoXhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXXT[4U2UW6qaXLpeIlwdiCxZjDoeY1idiCWOESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI1KM7:TR?= NEnBcJNUSU6JRWK=
human KYSE-450 cell NU\xWpJLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NE\Ed|ZKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOFUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{Nkeg{txO MkDMV2FPT0WU
human LCLC-103H cell M4DLeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{mwUWlvcGmkaYTpc44hd2ZiaIXtZY4hVEOOQz2xNFNJKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|MTDuUS=> Mkn0V2FPT0WU
human NCI-H810 cell M{LqTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3e0SGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi4NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN{MjFOwG0> NHT3VopUSU6JRWK=
human HUTU-80 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQCEQvF2= MkHyV2FPT0WU
human NCI-H460 cell M2frbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWPsRlhiUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ3OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{OzJO69VQ>? MXnTRW5ITVJ?
human HGC-27 cell NH70SWFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUnJcohq[mm2aX;uJI9nKGi3bXHuJGhISy1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M5KM7:TR?= MlzYV2FPT0WU
human HSC-2 cell MlPKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEnoTHhKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PjNibl2= MWPTRW5ITVJ?
human IA-LM cell NXnHdmtMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkTVTY5pcWKrdHnvckBw\iCqdX3hckBKSS2OTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|k{KM7:TR?= M4\iT3NCVkeHUh?=
human HMV-II cell NEnmRmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGhOXi2LSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|k1KM7:TR?= NU\kTZhzW0GQR1XS
human COLO-679 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIfRb|FKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlc6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|OUSg{txO NHXZc3FUSU6JRWK=
human NCI-H2122 cell NVjhfodyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn;kTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKxNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzIN88US=> NHfE[JlUSU6JRWK=
human CAL-39 cell NW\qUpE2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFXxOFlKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDFzIN88US=> NIDYW5RUSU6JRWK=
human SW954 cell NHu4[ZdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYLIXphQUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m1OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDN4IN88US=> NHrIUWRUSU6JRWK=
human LCLC-97TM1 cell NWrUSWdLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnfuTY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUm3WG0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52NESg{txO MnW5V2FPT0WU
human KYSE-270 cell MnXVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWTaXlNFUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVI4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNES1JO69VQ>? M{m1XHNCVkeHUh?=
human NB13 cell NHTwSphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXX6bJlOUW6qaXLpeIlwdiCxZjDoeY1idiCQQkGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PDdizszN MYPTRW5ITVJ?
human SK-LMS-1 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXf1bVNvUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MUXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNkS2JO69VQ>? NV;FbWZxW0GQR1XS
human SW620 cell M4nWWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHO2eVFKdmirYnn0bY9vKG:oIHj1cYFvKFOZNkKwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PDhizszN NU\L[mFpW0GQR1XS
human HCT-15 cell MnnHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4DESWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUG1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OTdizszN NH;ne3dUSU6JRWK=
human DU-145 cell NID4SFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3;RfGlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvMUS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OjFizszN MXnTRW5ITVJ?
human ST486 cell M2XGdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFfsUo9KdmirYnn0bY9vKG:oIHj1cYFvKFOWNEi2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OjFizszN NGjhUGpUSU6JRWK=
human A427 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYnlW401UW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45OjhizszN MkjHV2FPT0WU
human HT-1080 cell M4XsOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVrJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg1OiEQvF2= M1ryUnNCVkeHUh?=
human NCI-H2009 cell NIDBPWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{n4c2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFA6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56NkKg{txO MWnTRW5ITVJ?
human SK-LU-1 cell NHTMV5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyXLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg3PiEQvF2= Mny1V2FPT0WU
human SCC-4 cell NVXYeJc6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn\yTY5pcWKrdHnvckBw\iCqdX3hckBUS0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFc4KM7:TR?= NWXkNlNkW0GQR1XS
human NCI-H1299 cell NID4dWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlrhTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGyPVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh6IN88US=> M{TYfHNCVkeHUh?=
human NH-12 cell M{DSNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIfHWVhKdmirYnn0bY9vKG:oIHj1cYFvKE6KLUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QTFizszN NV\xNmVOW0GQR1XS
human SK-UT-1 cell NIjVSlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX\hSpU{UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OUKg{txO M{XLU3NCVkeHUh?=
human Bel7402 MonmVJJwdGmoZYLheIlwdiCjc4PhfS=> MVe3NkBp MnLPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEZXy3OFAzKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwQVAvQSEQvF2= NXLLclA4OjJ|MkCzOVQ>
human A388 cell NHLaSm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3SwXWlvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVQh|ryP M{fINHNCVkeHUh?=
human SW982 cell M3m4Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoPzTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVk6KM7:TR?= M{LsPHNCVkeHUh?=
In vivo In a mouse xenograft model of RPMI 8226 cells, Epothilone B (2.5 mg/kg–4 mg/kg) prolongs survival and suppresses tumor growth. [4] Similarly, in mouse xenograft models of prostate cancer cells, including DU145 and PC3, Epothilone B at the same dose also inhibits tumor growth. [6]

Protocol (from reference)

Kinase Assay:[1]
  • Tubulin polymerization assay:

    Calf brain microtubule proteins (MTP) are purified, which includes approximately 15%–20% microtubule associated proteins. The buffer (MES buffer) used for the Epothilone B-microtubule studies contains 0.1 M 2-morpholinoethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgCl2, and 3 M glycerol at pH 6.6. Samples for electron microscopy are placed on carbon-over-Parlodion-coated grids (300 mesh) and negatively stained with 2% uranyl acetate. Microtubule assembly in the presence or absence of Epothilone B is monitored spectrophotometrically by using a spectrophotometer equipped with a thermostatically regulated liquid circulator. The temperature is held at 35 °C and changes in turbidity (representative of polymer mass) are monitored at 350 nm. Effective concentration (EC0.01), defined as the interpolated concentration capable of inducing an initial slope of 0.01 OD/min rate, is calculated using the formula EC0.01 = concentration/slope and expressed as the mean with standard deviation obtained from three different concentrations.

Cell Research:[2]
  • Cell lines: KB3-1, KBV-1, Hela, and Hs578T cells
  • Concentrations: 0–1 μM
  • Incubation Time: 72 hours
  • Method: For mitotic block and aberrant mitosis, cells are plated either in 48-well plates (for trypan blue and cell counting) or onto coverslips. After 24 hours, cells are treated with Epothilone B and scored at regular intervals. For the cytotoxicity analysis, cells are counted and scored as trypan blue positive or negative. Concurrently, coverslips andaliquots of cells in the culture supernatant are fixed and stained with Hoechst33342 in PBS. These cells are scored for cells blocked at the G2/M transition and aberrant mitosis.
  • (Only for Reference)
Animal Research:[4]
  • Animal Models: Mice xenograft model of RPMI 8226 cells
  • Dosages: 2.5 mg/kg–4 mg/kg
  • Administration: Inject intravenously
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 102 mg/mL
(200.91 mM)
Ethanol 102 mg/mL
(200.91 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.

5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 507.68
Formula

C27H41NO6S

CAS No. 152044-54-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CCCC2(C(O2)CC(OC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00496600 Completed Drug: Patupilone|Drug: RAD001 Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers The State University of New Jersey July 2007 Phase 1
NCT00442741 Withdrawn Drug: Patupilone|Drug: Patupilone + Omeprazole Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00468260 Terminated Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00426140 Completed Drug: Patupilone Advanced Malignancies|Solid Tumors Novartis Pharmaceuticals|Novartis August 2006 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Patupilone (Epothilone B) | Patupilone (Epothilone B) supplier | purchase Patupilone (Epothilone B) | Patupilone (Epothilone B) cost | Patupilone (Epothilone B) manufacturer | order Patupilone (Epothilone B) | Patupilone (Epothilone B) distributor